These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy. Sekine H; Fukui I; Yamada T; Yamada T; Kojima S; Ohshima H J Urol; 1996 Jan; 155(1):94-8; discussion 98-9. PubMed ID: 7490908 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer. Jauhiainen K; Rintala E; Kaasinen E; Ruutu M; Alfthan O Arch Esp Urol; 1990; 43 Suppl 2():159-64. PubMed ID: 2129004 [TBL] [Abstract][Full Text] [Related]
27. [Mitomycin C in the topical treatment of superficial neoplasms of the bladder]. Milani C; Bassi PF; Meneghini A; Giunta A; Tejerizo JC; dal Bianco M; Zattoni F; Garbeglio A Arch Esp Urol; 1989 Oct; 42(8):761-7. PubMed ID: 2515812 [TBL] [Abstract][Full Text] [Related]
28. A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer. Harrison GS; Green DF; Newling DW; Richards B; Robinson MR; Smith PH Br J Urol; 1983 Dec; 55(6):676-9. PubMed ID: 6418263 [TBL] [Abstract][Full Text] [Related]
29. Conservative treatment of diffuse carcinoma in situ of the bladder with repeated courses of intravesical therapy. Mukamel E; deKernion JB Br J Urol; 1989 Aug; 64(2):143-6. PubMed ID: 2504435 [TBL] [Abstract][Full Text] [Related]
30. Mitomycin C resorption following repeated intravesical instillations using different instillation times. van Helsdingen PJ; Rikken CH; Sleeboom HP; de Bruyn EA; Tjaden UR Urol Int; 1988; 43(1):42-6. PubMed ID: 3131943 [TBL] [Abstract][Full Text] [Related]
32. Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients. Prout GR; Griffin PP; Nocks BN; DeFuria MD; Daly JJ J Urol; 1982 Jun; 127(6):1096-8. PubMed ID: 6806488 [TBL] [Abstract][Full Text] [Related]
33. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. Soloway MS; Jordan AM; Murphy WM Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268 [TBL] [Abstract][Full Text] [Related]
34. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711 [TBL] [Abstract][Full Text] [Related]
35. Reduced bladder capacity in patients receiving intravesical chemoprophylaxis with mitomycin C. Eijsten A; Knönagel H; Hotz E; Brütsch HP; Hauri D Br J Urol; 1990 Oct; 66(4):386-8. PubMed ID: 2121309 [TBL] [Abstract][Full Text] [Related]
36. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. Zincke H; Benson RC; Hilton JF; Taylor WF J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685 [TBL] [Abstract][Full Text] [Related]
37. Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy. Pisters LL; Tykochinsky G; Wajsman Z J Urol; 1991 Dec; 146(6):1514-7. PubMed ID: 1942330 [TBL] [Abstract][Full Text] [Related]
38. Treatment of superficial carcinoma of the bladder. Paulson DF Prog Clin Biol Res; 1984; 162B():193-209. PubMed ID: 6209720 [No Abstract] [Full Text] [Related]